Genentech, a member of the Roche Group, has more than 40 years of experience in the field of biotechnology. Genentech is researching and developing new treatments for people living with a range of eye diseases that cause significant visual impairment and blindness, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), geographic atrophy (GA), and other retinal diseases.
Social Media:
Twitter: https://www.twitter.com/genentecheye
LinkedIn: https://www.linkedin.com/company/genentech/
Facebook: https://www.facebook.com/Genentech/
Instagram: https://www.instagram.com/genentech/